IL158550A0 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same - Google Patents

Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Info

Publication number
IL158550A0
IL158550A0 IL15855002A IL15855002A IL158550A0 IL 158550 A0 IL158550 A0 IL 158550A0 IL 15855002 A IL15855002 A IL 15855002A IL 15855002 A IL15855002 A IL 15855002A IL 158550 A0 IL158550 A0 IL 158550A0
Authority
IL
Israel
Prior art keywords
inhibitors
identifying
methods
same
inhibitory factor
Prior art date
Application number
IL15855002A
Other languages
English (en)
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of IL158550A0 publication Critical patent/IL158550A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL15855002A 2001-05-24 2002-05-24 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same IL158550A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29364201P 2001-05-24 2001-05-24
PCT/US2002/016963 WO2002094203A2 (en) 2001-05-24 2002-05-24 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Publications (1)

Publication Number Publication Date
IL158550A0 true IL158550A0 (en) 2004-05-12

Family

ID=23129922

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15855002A IL158550A0 (en) 2001-05-24 2002-05-24 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Country Status (24)

Country Link
US (14) US7105519B2 (enExample)
EP (1) EP1389110B1 (enExample)
JP (1) JP4346312B2 (enExample)
KR (1) KR100896973B1 (enExample)
CN (1) CN1523989A (enExample)
AR (1) AR036032A1 (enExample)
AT (1) ATE461920T1 (enExample)
AU (2) AU2002303906B2 (enExample)
BR (1) BR0209948A (enExample)
CA (1) CA2447103A1 (enExample)
CZ (1) CZ20033503A3 (enExample)
DE (1) DE60235750D1 (enExample)
ES (1) ES2342877T3 (enExample)
HU (1) HUP0500101A3 (enExample)
IL (1) IL158550A0 (enExample)
MX (1) MXJL03000038A (enExample)
MY (1) MY140679A (enExample)
NZ (1) NZ529244A (enExample)
PL (1) PL367127A1 (enExample)
PT (1) PT1389110E (enExample)
RU (1) RU2327695C2 (enExample)
UY (1) UY27304A1 (enExample)
WO (1) WO2002094203A2 (enExample)
ZA (1) ZA200309738B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4202763B2 (ja) * 2001-03-29 2008-12-24 サイトカイン・ファーマサイエンシズ・インコーポレーテッド マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20060034832A1 (en) 2002-04-26 2006-02-16 Haruhide Kimura Cell death inhibitor
MXPA05000081A (es) 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7364869B2 (en) * 2003-07-29 2008-04-29 The J. David Gladstone Institutes Method of detecting antigen-specific T lymphocytes
AU2004268941A1 (en) * 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
AU2005228426B2 (en) * 2004-03-29 2010-07-15 North Shore-Long Island Jewish Research Institute Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor
DE102004029573A1 (de) * 2004-06-18 2005-12-29 Gambro Lundia Ab MIF-Adsorbent
AU2004323369A1 (en) * 2004-09-17 2006-03-23 Siang Beng Chng System and method for batch conversion of RFID tag to RFID label
JP2008534502A (ja) * 2005-03-24 2008-08-28 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としてのチエノピリジノン誘導体
RU2008116720A (ru) * 2005-09-26 2009-11-10 Эвиджен, Инк. (Us) Способы лечения наркозависимости и пагубных привычек в поведении
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
JP5523095B2 (ja) 2006-03-24 2014-06-18 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ 修飾マクロファージ遊走阻止因子阻害剤
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes
US7622256B2 (en) * 2006-05-31 2009-11-24 Avigen, Inc. Method for selecting compounds that modulate MIF-induced expression of ICAM-1 and/or VCAM-1
US7845914B2 (en) * 2007-02-15 2010-12-07 Deere & Company Self-priming fast fill sprayer pump system
US9272034B2 (en) * 2007-10-04 2016-03-01 The Regents Of The University Of California Treatment of conditions related to shock
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
PT2592933T (pt) * 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
EP2621521A4 (en) 2010-10-02 2014-04-23 Univ California MINIMIZING DARMDYS FUNCTIONS
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
DK2844250T3 (en) 2012-05-01 2018-01-08 Translatum Medicus Inc METHODS OF TREATMENT AND DIAGNOSTICATION OF EYE DISEASES CONCERNING BLINDNESS
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
CN108137505B (zh) * 2015-07-17 2021-07-06 富士胶片株式会社 含氮杂环化合物
CN111518077B (zh) * 2018-01-17 2021-02-26 杭州阿诺生物医药科技有限公司 一种新型抗肿瘤ido抑制剂的制备方法
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
JP7493454B2 (ja) 2018-04-13 2024-05-31 キャンサー・リサーチ・テクノロジー・リミテッド Ｂｃｌ６阻害剤
PL3814347T3 (pl) 2018-06-27 2023-07-24 Bristol-Myers Squibb Company Związki naftyrydynonu użyteczne jako aktywatory komórek t
WO2020006018A1 (en) 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Substituted naphthyridinone compounds useful as t cell activators
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
BR112022012179A2 (pt) 2019-12-23 2022-09-06 Bristol Myers Squibb Co Compostos de quinazolina substituída úteis como ativadores de célula t
CN115103841B (zh) * 2019-12-23 2024-12-27 百时美施贵宝公司 可用作t细胞激活剂的经取代的喹啉酮基哌嗪化合物
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
KR20220120624A (ko) 2019-12-23 2022-08-30 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 피페라진 유도체
CN113121435B (zh) * 2021-04-20 2022-08-30 辽宁大学 一种2,4-二氯喹啉类化合物的合成方法
CN119074725A (zh) * 2024-09-11 2024-12-06 北京大学第一医院(北京大学第一临床医学院) 靶向mif在制备用于治疗特应性皮炎的药物中应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4299814A (en) * 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4284768A (en) * 1980-07-02 1981-08-18 American Home Products Corporation 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
NZ211191A (en) 1984-02-22 1988-01-08 Wellcome Found Cloning of dna for protozoal antigens
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
AU592753B2 (en) 1984-05-24 1990-01-25 Ciba-Geigy Ag Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications
JPH0672158B2 (ja) 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4708937A (en) * 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8602626D0 (en) * 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
DE3789413T2 (de) 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463037A1 (en) 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor
FI82144C (fi) * 1989-03-22 1991-01-10 Wallac Oy Foerfarande foer samtidig bestaemning av flera ligander.
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5328990A (en) * 1991-04-26 1994-07-12 The United States Of America As Represented By The Department Of Health And Human Services Isolation of macrophage migration inhibition factor from ocular lens
CA2054602C (en) * 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
WO1994026307A1 (en) 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
US5650295A (en) * 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
US5955203A (en) 1994-10-05 1999-09-21 Simpson Timber Company Resin-coated overlays for solid substrates
AU4365796A (en) 1994-11-16 1996-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
DE19601697A1 (de) 1996-01-18 1997-07-24 Wacker Chemie Gmbh Redispergierbare Tackifierpulver
US6420188B1 (en) * 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
WO1997039326A2 (en) 1996-04-18 1997-10-23 Ariad Pharmaceuticals, Inc. In vitro fluorescence polarization assay
US5883224A (en) * 1996-04-19 1999-03-16 Cytokine Sciences, Inc. Characterization of transfer factors and methods of use
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6413939B1 (en) * 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
JP2002521690A (ja) * 1998-07-28 2002-07-16 バイオメトリック イメージング インコーポレイテッド 細胞運動性アッセイのための装置および方法
AU776825B2 (en) 1998-08-07 2004-09-23 Immunex Corporation Molecules designated LDCAM
US6214343B1 (en) * 1999-05-24 2001-04-10 Ophidian Pharmaceuticals, Inc. Prevention and treatment of necrotizing enterocolitis
CA2389229A1 (en) * 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
CA2434671A1 (en) 2001-01-12 2002-09-06 The Picower Institute For Medical Research Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
JP4202763B2 (ja) 2001-03-29 2008-12-24 サイトカイン・ファーマサイエンシズ・インコーポレーテッド マクロファージ遊走阻止因子レセプターとしてのｍｈｃクラスｉｉ不変鎖ポリペプチド使用のための方法及び組成物
UY27304A1 (es) * 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
EP1424336A4 (en) 2001-09-03 2004-11-10 Takeda Chemical Industries Ltd 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE
FR2829491B1 (fr) 2001-09-12 2005-09-30 Diverchim Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase
AU2002365941A1 (en) 2001-12-05 2003-09-02 North Shore-Long Island Jewish Research Institute Methods of diagnosis, monitoring and treatment of fertility
US20040019921A1 (en) 2001-12-19 2004-01-29 Fingerle-Rowson Gunter R. Non-human mammal with disrupted or modified MIF gene, and uses thereof
US20060034832A1 (en) 2002-04-26 2006-02-16 Haruhide Kimura Cell death inhibitor
AU2003229142A1 (en) 2002-06-07 2003-12-22 Cortical Pty Ltd Naphthalene derivatives which inhibit the cytokine or biological activity of macrophage inhibitory factor (MIF)
AU2003233244B2 (en) 2002-06-07 2010-05-20 Cortical Pty Ltd Therapeutic molecules and methods-1
AU2003260810A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
EP1568697A4 (en) 2002-12-05 2006-03-08 Takeda Pharmaceutical 1,3-BENZOTHIAZINONE DERIVATIVES, THEIR MANUFACTURING METHOD AND USE
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7361474B2 (en) 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
AU2004268941A1 (en) 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
JP2008534502A (ja) * 2005-03-24 2008-08-28 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としてのチエノピリジノン誘導体

Also Published As

Publication number Publication date
WO2002094203A3 (en) 2003-04-10
NZ529244A (en) 2006-04-28
CA2447103A1 (en) 2002-11-28
JP2005500266A (ja) 2005-01-06
RU2327695C2 (ru) 2008-06-27
MXJL03000038A (es) 2004-12-03
WO2002094203A2 (en) 2002-11-28
EP1389110B1 (en) 2010-03-24
US7230106B2 (en) 2007-06-12
US20070197547A1 (en) 2007-08-23
US7084141B2 (en) 2006-08-01
HUP0500101A2 (hu) 2005-05-30
ES2342877T3 (es) 2010-07-16
US20070021440A1 (en) 2007-01-25
US7157469B2 (en) 2007-01-02
US20060205734A1 (en) 2006-09-14
PL367127A1 (en) 2005-02-21
AR036032A1 (es) 2004-08-04
AU2007201493A1 (en) 2007-04-26
MY140679A (en) 2010-01-15
US20060199827A1 (en) 2006-09-07
ZA200309738B (en) 2004-10-04
US7238809B2 (en) 2007-07-03
HUP0500101A3 (en) 2009-09-28
US20060194792A1 (en) 2006-08-31
US20060235023A1 (en) 2006-10-19
US7105519B2 (en) 2006-09-12
US7732146B2 (en) 2010-06-08
US20050282236A1 (en) 2005-12-22
US20050287617A1 (en) 2005-12-29
US20060199825A1 (en) 2006-09-07
PT1389110E (pt) 2010-07-01
CZ20033503A3 (cs) 2004-08-18
ATE461920T1 (de) 2010-04-15
US7192961B2 (en) 2007-03-20
US20030195194A1 (en) 2003-10-16
KR100896973B1 (ko) 2009-05-14
US7432374B2 (en) 2008-10-07
RU2003132534A (ru) 2005-04-20
US7435737B2 (en) 2008-10-14
BR0209948A (pt) 2004-12-21
US7514225B2 (en) 2009-04-07
KR20040041095A (ko) 2004-05-13
US7235565B2 (en) 2007-06-26
CN1523989A (zh) 2004-08-25
US20060194793A1 (en) 2006-08-31
US7192955B2 (en) 2007-03-20
US7129236B2 (en) 2006-10-31
AU2002303906B2 (en) 2007-06-28
US20060194818A1 (en) 2006-08-31
US20070232613A1 (en) 2007-10-04
US20060094727A1 (en) 2006-05-04
JP4346312B2 (ja) 2009-10-21
DE60235750D1 (de) 2010-05-06
UY27304A1 (es) 2002-12-31
US7202248B2 (en) 2007-04-10
EP1389110A2 (en) 2004-02-18
EP1389110A4 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
HUP0500101A3 (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
ZA200507170B (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
PL375447A1 (en) Protein kinase inhibitors and uses thereof
AU2003302248A8 (en) Method and system for determining characteristics of substrates employing fluid geometries
EP1507756A4 (en) CCR9 INHIBITORS AND USE THEREOF
AU2003303128A1 (en) Inhibitors and methods of use thereof
IL164704A0 (en) System and method for use of multiple applications
EP1496910A4 (en) KINASE INHIBITORS
AU2003256945A8 (en) Vapor-liquid contact trays and method employing same
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
EP1549316A4 (en) HAMMER OF TFGbeta
AU2002361861A1 (en) SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
AU2003247659A8 (en) Vapor-liquid contact tray and method employing same
AU2003220437A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
IL160620A0 (en) Combinations comprising cox-2 inhibitors and aspirin
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
GB0124700D0 (en) Method for the secure distribution and use of media electronic media
HK1060984A (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2003210741A1 (en) Ptpase inhibitors and methods of using the same
HK1083069A (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2003269954A8 (en) Measurement systems and methods
GB0109278D0 (en) Enzyme inhibitors
EP1441034A4 (en) METHOD FOR EVALUATING PHOSPHATASE INHIBITORS
IL165870A0 (en) Use of chymase inhibitors for the prevention and/or